09:26:50 EDT Thu 30 May 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:PHIO - PHIO PHARMACEUTICALS CORP - https://phiopharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PHIO - Q0.50.70·0.85640.10.7489    4.10  0.50May 29May 2815 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-28 07:31U:PHIONews ReleasePhio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
2024-05-23 17:01U:PHIONews ReleasePhio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
2024-05-17 09:01U:PHIONews ReleasePhio Pharmaceuticals Secures New Investor
2024-05-16 08:00U:PHIONews ReleasePhio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
2024-05-15 13:00U:PHIONews ReleasePhio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
2024-05-09 17:26U:PHIONews ReleasePhio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
2024-04-30 07:30U:PHIONews ReleasePhio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
2024-04-22 13:10U:PHIONews ReleaseIntratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
2024-04-16 07:30U:PHIONews ReleasePhio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
2024-04-11 07:30U:PHIONews ReleasePhio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
2024-04-03 07:30U:PHIONews ReleaseNational Spotlight Features Phio's Innovative RNAi Technology Platform
2024-04-02 07:30U:PHIONews ReleasePhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
2024-03-21 07:30U:PHIONews ReleasePhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
2024-03-13 14:00U:PHIONews ReleasePhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
2024-03-06 10:31U:PHIONews ReleasePhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders
2024-01-31 08:00U:PHIONews ReleasePhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
2023-12-07 08:00U:PHIONews ReleasePhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
2023-11-09 16:30U:PHIONews ReleasePhio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-09 07:30U:PHIONews ReleasePhio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
2023-11-03 12:00U:PHIONews ReleasePhio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control